Braveheart Bio's Hengrui-licensed cardiac therapy shows positive mid-stage trial results

Braveheart Bio announced that its heart muscle therapy, licensed from Jiangsu Hengrui Pharmaceuticals, has achieved a positive outcome in a Phase 2 trial.

The mid-stage study met its primary endpoints, demonstrating improvement in the targeted cardiac condition, which mirrors recent positive data from Cytokinetics.

The result represents the company's second clinical success with the Hengrui-derived drug, potentially advancing it toward later-stage testing and eventual market entry.